Greenwich Biosciences Inc.
5750 Fleet Street
About Greenwich Biosciences Inc.
Greenwich Biosciences Inc. is the US subsidiary of GW Pharmaceuticals plc, which is the global leader in developing cannabinoid-based medicines.
Founders: Geoffrey Guy and Brian Whittle
5 articles with Greenwich Biosciences Inc.
GW Pharmaceuticals Reports Positive Phase 3 Pivotal Trial Results for EPIDIOLEX® (cannabidiol) Oral Solution in Patients with Seizures Associated With Tuberous Sclerosis Complex
GW Pharmaceuticals plc and its U.S. subsidiary Greenwich Biosciences Inc. (NASDAQ: GWPH, GW, the Company or the Group), the world leader in the science, development, and commercialization of cannabinoid prescription medicines, today announced positive top-line results of a randomized, double-blind, placebo-controlled Phase 3 clinical trial of EPIDIOLEX
GW Pharmaceuticals, with offices in London, UK and Carlsbad, Calif., announced that its Epidiolex (cannabidiol) for seizures associated with Lennox-Gastaut syndrome (LGS) or Draven syndrome is now available in the United States.
Zogenix announced positive top-line data from its second confirmatory Phase III clinical trial of ZX008 (low-dose fenfluramine hydrochloride) for children and young adults with Dravet syndrome.
6/26/2018In a first of its kind ruling, the U.S. Food and Drug Administration approved GW Pharmaceuticals’ Epidiolex, a cannabis-based treatment for seizures associated with two rare forms of epilepsy, Lennox-Gastaut syndrome (LGS) and Dravet syndrome.
GW Pharmaceuticals and Its U.S. Subsidiary Greenwich Biosciences Announce Publication of Landmark Epidiolex (Cannabidiol) Study in The Lancet
Treatment with Epidiolex was generally well tolerated, with a safety profile consistent with prior reported experience.